Susceptibilities of Candida species isolated from the lower gastrointestinal tracts of high-risk patients to the new semisynthetic echinocandin LY303366 and other antifungal agents

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 9, 1998, Pages 2446-2448

  Zhanel, George G ^a,b   Karlowsky, James A ^a,b   Zelenitsky, Sheryl A ^a   Turik, Michael A ^c   Hoban, Daryl J ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b HEALTH SCIENCES CENTRE   (Canada)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; ECHINOCANDIN B DERIVATIVE; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; CANADA; CANDIDA ALBICANS; CANDIDA GLABRATA; CONTROLLED STUDY; DRUG SENSITIVITY; FECES ANALYSIS; GASTROINTESTINAL INFECTION; HIGH RISK PATIENT; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

EID: 0031713717     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.9.2446     Document Type: Article

References (8)

1. Edwards, J. E. 1995. Candida species, p. 2289-2305. In G. L. Mandell, J. E. Bennett, and R. Dolin (ed.), Principles and practice of infectious diseases, 4th ed. Churchill Livingstone, Inc., New York, N.Y.
2. Ernst, M. E., M. E. Klepser, E. J. Wolfe, and M. A. Pfaller. 1996. Antifungal dynamics of LY303366, an investigational echinocandin B analog, against Candida ssp. Diagn. Microbiol. Infect. Dis. 26:125-131.
3. Karlowsky, J. A., G. G. Zhanel, K. A. Klym, D. J. Hoban, and A. M. Kabani. 1997. Candidemia in a Canadian tertiary care hospital from 1976 to 1996. Diagn. Microbiol. Infect. Dis. 29:5-9.
4. Kennedy, M. J., P. A. Volz, C. A. Edward, and R. J. Yancey. 1987. Mechanisms of association of Candida albicans with intestinal mucosa. J. Med. Microbiol. 24:333-341.
5. Merz, W. G., and G. D. Roberts. 1995. Detection and recovery of fungi from clinical specimens, p. 709-722. In P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology. American Society for Microbiology, Washington, D.C.
6. National Committee for Clinical Laboratory Standards. 1995. Reference method for broth dilution antifungal susceptibility testing of yeasts. Tentative standard M27-T. National Committee for Clinical Laboratory Standards, Villanova, Pa.
7. Pfaller, M. A., S. Messer, and S. Coffman. 1997. In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY303366, and other antifungal agents. Antimicrob. Agents Chemother. 41:763-766.
8. Zhanel, G. G., J. A. Karlowsky, G. A. J. Harding, T. V. Balko, S. A. Zelenitsky, M. Friesen, A. Kabani, M. Turik, and D. J. Hoban. 1997. In vitro activity of a new semisynthetic echinocandin, LY303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species. Antimicrob. Agents Chemother. 41:863-865.